Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published February 3, 2020 | Supplemental Material
Journal Article Open

Nanoparticles containing a combination of a drug and an antibody for the treatment of breast cancer brain metastases

Abstract

In women with human epidermal growth factor 2 (HER2)-positive breast cancer, the improved control of systemic disease with new therapies has unmasked brain metastases that historically would have remained clinically silent. The efficacy of therapeutic agents against brain metastases is limited by their inability to permeate the blood–brain and blood–tumor barriers (BBB and BTB) in therapeutic amounts. Here, we investigate the potential of mucic acid-based, targeted nanoparticles designed to transcytose the BBB/BTB to deliver a small molecule drug, camptothecin (CPT), and therapeutic antibody, Herceptin, to brain metastases in mice. Treatment with BBB-targeted combination CPT/Herceptin nanoparticles significantly inhibits tumor growth compared to free CPT/Herceptin and BBB-targeted nanoparticles carrying CPT alone. Though not as efficacious, BBB-targeted nanoparticles carrying only Herceptin also elicit considerable antitumor activity. These results demonstrate the potential of the targeted nanoparticle system for the delivery of an antibody alone or in combination with other drugs across the BBB/BTB to improve the therapeutic outcome.

Additional Information

© 2020 American Chemical Society. Received: November 12, 2019; Revised: January 6, 2020; Accepted: January 9, 2020; Published: January 9, 2020. This material is based upon work supported by the National Science Foundation Graduate Research Fellowship Program (DGE-1745301; to E.A.W.). Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the National Science Foundation. This work was supported by the National Cancer Institute Grant (CA 151819). Author Contributions: E.A.W. and M.E.D. designed the research. E.A.W. performed the research. E.A.W. and M.E.D. analyzed data, and E.A.W. and M.E.D. wrote the paper. The authors declare no competing financial interest.

Attached Files

Supplemental Material - mp9b01167_si_001.pdf

Files

mp9b01167_si_001.pdf
Files (740.6 kB)
Name Size Download all
md5:a11c823fe9f5d5107cf5d846e551977f
740.6 kB Preview Download

Additional details

Created:
August 22, 2023
Modified:
October 18, 2023